



(19)

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 384 482 A1

(12)

EUROPEAN PATENT APPLICATION
published in accordance with Art. 158(3) EPC

(43) Date of publication:
28.01.2004 **Bulletin 2004/05**

(51) Int Cl.7: **A61K 31/7008, A61K 31/07,**
A61K 31/203, A61K 31/00,
A61K 31/40, A61K 31/42,
A61P 17/16

(21) Application number: **02705098.8**

(86) International application number:
PCT/JP2002/002271

(22) Date of filing: **11.03.2002**

(87) International publication number:
WO 2002/076470 (03.10.2002 Gazette 2002/40)

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**

- **SAKAI, Shingo**
Odawara-shi, Kanagawa 250-0055 (JP)
- **INOUE, Shintaro**
Odawara-shi, Kanagawa 250-0851 (JP)

(30) Priority: **27.03.2001 JP 2001089314**

(74) Representative: **VOSSIUS & PARTNER**
Siebertstrasse 4
81675 München (DE)

(71) Applicant: **Kanebo, Limited**
Sumida-ku, Tokyo 131-0031 (JP)

(72) Inventors:

- **SAYO, Tetsuya**
Odawara-shi, Kanagawa 250-0863 (JP)

(54) EXTERNAL SKIN COMPOSITIONS

(57) The external skin care composition of the present invention comprises N-acetylglucosamine and at least one member selected from the group consisting of retinoid and pro-vitamin A.

The external skin care composition of the present

invention has an effect of promoting the production of epidermal hyaluronic acid and can retain firmness and moisture of the skin.

Description**TECHNICAL FIELD**

5 [0001] The present invention relates to an external skin care composition which can prevent or improve wrinkled skin, dry skin, tanned skin and aged skin while maintaining firmness and moisture of the skin and, more particularly, to an external skin care composition containing N-acetylglucosamine and at least one member selected from the group consisting of retinoid and pro-vitamin A.

10 **BACKGROUND ART**

[0002] Hyaluronic acid has various functions such as retention of moisture in intercellular spaces, retention of cell structures by formation of a jelly-like matrix, retention of humidity and elasticity of the skin, resistance to an external force such as mechanical disorder, and prevention of bacterial infection (BIO INDUSTRY, Vol. 8, page 346, 1991).

15 [0003] It has been reported that the intensity of the staining signal of hyaluronic acid in the epidermis is reduced with aging (J. Invest. Dermatol., 102, 385, 1994), and that hyaluronic acid at solar elastosis site under irradiation with ultraviolet light is scarcely detected (Clin. Dermatol. (special number 5) 51, 53, 1997; Nagoya Med. J., 41, 27, 1997), thus causing dry skin and deterioration of firmness and elasticity of the skin, resulting in increase of wrinkles. To improve these skin conditions, a method of retaining moisture on the surface of the skin by applying a cosmetic composition 20 containing hyaluronic acid formulated therein has been employed. However, since hyaluronic acid, as a large polymer, can not penetrate into the skin, a drastic improvement can not be expected. Therefore, it is expected to develop a substance capable of drastically improving cutaneous functions by promoting a cellular ability of production of hyaluronic acid.

25 [0004] As a substance capable of promoting the production of hyaluronic acid in epidermis, retinoic acid has been known so far. Retinoic acid is an essential substance which intrinsically exists in the epidermis and plays an important roles in the growth and differentiation of epidermal cells. Retinoic acid has widely used as an agent for restoring skin characteristics and an agent for reintegration of the skin in foreign countries in order to treat various dermatopathies, for example, acne vulgaris, fine wrinkles, psoriasis and age spots.

30 [0005] Various reports with respect to the effect of retinoic acid on (photo)aging have been made and its improving effect on the formation of fine wrinkles is recognized (Plastic Surgery, 42: 801, 1999; J. Dermatol., 122, 91, 1990). Also it has been reported that deposition of mucopolysaccharides such as hyaluronic acid increases and the histological change of the photoaged skin is improved by applying retinoic acid (J. Dermatol. Sci., 11, 177, 1996). Therefore, it is considered that the deposition of hyaluronic acid, as an epidermal matrix component, and an increase in moisture achieved thereby may contribute remarkably to the effect of smoothing the skin surface of retinoic acid (The Japanese 35 Journal of Dermatology, Vol. 110, No. 12, 1878, 2000) and an epidermal hyaluronic acid production promoting ingredient is useful for anti-wrinkling (prevention of formation of wrinkles or improvement of wrinkles) (FRAGRANCE JOURNAL, 4, 49, 1998).

40 [0006] However, retinoic acid causes skin irritation and it is required to formulate an external preparation containing low-concentration retinoic acid in order to prevent skin irritation. On the other hand, retinol or retinyl ester with less irritation must be metabolized in vivo into retinoic acid, as an activator, and it has exerts a smaller effect as compared with retinoic acid when the skin is benefitted. Therefore, it has been required to develop an external skin care ingredient which does not cause side effect such as skin irritation while maintaining the effect of retinoic acid. The present invention is based on such finding that a combination of a retinoid and N-acetylglucosamine gives a synergistic improvement in the synthesis of hyaluronic acid of keratinocytes (epidermal cells).

45 [0007] Under these circumstances, an object of the present invention is to provide an external skin care ingredient which exerts a synergistic effect of promoting the production of hyaluronic acid by using in combination with a retinoid.

DISCLOSURE OF THE INVENTION

50 [0008] In order to achieve the object described above, the present inventors have studied about an ability of promoting the hyaluronic acid production in various substances and found that N-acetylglucosamine acts synergically in combination with retinoids and also found that it exerts noticeably excellent effect of promoting the hyaluronic acid production by using in combination with pro-vitamin A. Thus, the present invention has been completed based on these findings.

55 [0009] Therefore, the present invention is directed to an external skin care composition containing N-acetylglucosamine and at least one member selected from the group consisting of a retinoid and pro-vitamin A.

BRIEF DESCRIPTION OF THE DRAWINGS

[0010]

5 Fig. 1 is a graph showing a synergistic effect of promoting the production of hyaluronic acid in human keratinocytes by using N-acetylglucosamine in combination with various retinoids.
 Fig. 2 is a graph showing a synergistic effect of promoting the hyaluronic acid production in human keratinocytes by using N-acetylglucosamine in combination with β -carotene.

10 BEST MODE FOR CARRYING OUT THE INVENTION

[0011] In the present invention, the external skin care composition generally refers to all compositions to be applied onto the skin including scalp, and includes medicaments, quasi-drugs, cosmetic compositions, bath medicines, hair growth promoters and scalp tonics.

15 [0012] According to the present invention, by formulating an effective amount of N-acetylglucosamine into the external skin care composition containing a retinoid, performances of the composition is substantially improved. Alternatively, it is possible to impart the same performances of a composition containing a high level of a retinoid to the composition by a combination of a low level (low concentration) of a retinoid and N-acetylglucosamine. Also it is possible to exert an excellent effect of promoting the production of hyaluronic acid by using in combination with pro-vitamin A which merely exerts a slight effect of promoting the hyaluronic acid production alone.

20 [0013] N-acetylglucosamine as the first essential ingredient of the present invention includes, but is not limited to, synthetic and fermentation products, and decomposition products obtained by decomposing chitin of crab, prawn or the like.

[0014] The amount of N-acetylglucosamine to be formulated into the external skin care composition is preferably controlled within a range from 0.001 to 10% by weight (hereinafter merely referred to as %), and particularly preferably from 0.01 to 5%, based on the total amount of the composition.

25 [0015] A retinoid as the second essential ingredient of the present invention, includes retinoic acid, retinal, retinol and fatty acid retinyl ester; and dehydroretinol, dehydroretinol and fatty acid dehydroretinyl ester. Pro-vitamin A is a compound having a retinilidene residue in the molecule and specific examples thereof include α -carotene, β -carotene, cryptoxanthin and echinenone. Two or more members of a retinoid and pro-vitamin A may be used in combination. Among these, retinoic acid is particularly preferable in view of the effect.

30 [0016] Retinoic acid includes the following isomers of retinoic acid, for example, all-trans-retinoic acid, 13-cis-retinoic acid, 11-cis-retinoic acid, 9-cis-retinoic acid and 3,4-dehydro-retinoic acid. Among these, all-trans-retinoic acid and 13-cis-retinoic acid, which are widely used as a remedy for acne vulgaris and photoaging in foreign countries, are preferable.

35 [0017] Retinol include the following isomers of retinol, for example, all-trans-retinol, 13-cis-retinol, 11-cis-retinol, 9-cis-retinol and 3,4-dehydro-retinol. Among these, all-trans-retinol and 13-cis-retinol are preferably because they are widely put on the market.

40 [0018] The fatty acid retinyl ester is a fatty acid ester of retinol. The fatty acid retinyl ester includes, but is not limited to, retinyl palmitate, retinyl formate, retinyl acetate, retinyl propionate, butyric acid retinyl, retinyl valerate, retinyl isovalerate, retinyl hexanoate, retinyl heptanoate, retinyl octanoate, retinyl nonanoate, retinyl decanoate, retinyl undecanoate, retinyl laurate, retinyl tridecanoate, retinyl myristate, retinyl pentadecanoate, retinyl heptadecanoate, stearic acid retinyl, isostearic acid ester, retinyl nonadecanoate, retinyl arachidonate, retinyl arachidonate, retinyl linoleate and retinyl oleate. The fatty acid moiety may be straight-chain or branched, or saturated or unsaturated.

45 [0019] As the fatty acid retinyl ester used in the present invention, commercially available retinyl palmitate, retinyl acetate and retinyl propionate are preferable.

[0020] The amount of the retinoid and/or pro-vitamin A to be formulated into the external skin care composition is preferably within a range from 0.0001 to 10%, and more preferably from 0.01 to 1%, based on the total amount of the composition.

50 [0021] The external skin care composition of the present invention appropriately contain tar colors; silicone oils such as dimethylpolysiloxane, methylphenylpolysiloxane, and cyclic silicone; carotenoid pigments such as lutein, astaxanthin, and fucoxanthin; color pigments such as iron oxide; antiseptics such as paraben and phenoxyethanol; hydrocarbons such as paraffin and petrolatum; vegetable oils such as olive squalane, rice squalane, whole rise oil, jojoba oil, castor oil, safflower oil, olive oil, macadamia nuts oil, and sunflower oil; waxes such as beeswax, Japan wax, and carnauba wax; ester oils such as octyldodecyl myristate, cetyl palmitate, isostearyl isostearate, and isopropyl myristate; lower alcohols such as ethanol; higher alcohols such as cetanol, behenyl alcohol, stearyl alcohol, and long-chain branched aliphatic alcohol; sterols and derivatives, such as cholesterol, phytosterol, branched fatty acid cholesterol ester, and macadamia nuts fatty acid phytosteryl ester; processed oils such as hardened oil; higher fatty acids such

as stearic acid, myristic acid, isostearic acid, oleic acid, iso type long-chain fatty acid, and anti-iso type long-chain fatty acid; terpenes such as limonene and hydrogenated bisabolol; triglycerides such as tricapryl glyceryl caprate, glyceryl 2-ethylhexanoate, triiso type long-chain fatty acid glyceryl, and glyceryl tripalmitate; anionic surfactants such as sodium cetyl sulfate and N-stearoyl-L-glutamate; nonionic surfactants such as polyoxyethylene alkyl ether, polyoxyethylene fatty acid ester, polyoxyethylene polyhydric alcohol fatty acid ester, polyoxyethylene hydrogenated castor oil, polyhydric alcohol fatty acid ester, modified silicone (e.g. polyoxyethylene-modified silicone), polyglycerin fatty acid ester, and sucrose ester; cationic surfactants such as tetraalkylammonium salt; amphoteric surfactants such as betaine type, sulfobetaine type and sulfoamino acid type surfactants; natural surfactants such as lecithin, lysophosphatidylcholine, ceramide, and cerebroside; pigments such as titanium oxide and zinc oxide; antioxidants such as dibutylhydroxytoluene; mineral salts such as sodium chloride, magnesium chloride, sodium sulfate, potassium nitrate, sodium sulfate, sodium metasilicate, and calcium chloride; organic acids and salts thereof, such as sodium citrate, potassium acetate, sodium succinate, sodium aspartate, sodium lactate, dichloroacetic acid, mevalonic acid, and glycyrrhizinic acid; organic amines and salts thereof, such as ethanolamine hydrochloride, ammonium nitrate, arginine hydrochloride, diisopropylamine salt, urea, and decarboxycarnosine; chelating agents such as edetic acid; thickeners such as xanthan gum, carboxyvinyl polymer, carrageenan, pectin, alkyl-modified carboxyvinyl polymer, and agar; neutralizers such as potassium hydroxide, diisopropanolamine, and triethanolamine; ultraviolet absorbers such as hydroxymethoxybenzophenone sulfonate; polyhydric alcohols such as dipropylene glycol, maltitol 1,3-butylene glycol, glycerin, propylene glycol, sorbitol, diglycerin, and raffinose; various amino acids; vitamins such as ascorbic acid, biotin, and tocopherol; and vitamin derivatives such as ascorbic acid phosphate ester salt and tocopherol nicotinate, in addition to the ingredients described above, as far as the object of the present invention can be achieved.

[0022] Furthermore, the effect of preventing formation of wrinkles is more enhanced by appropriately formulating dermal hyaluronic acid production promoters, such as N-methyl-L-serine and yeast extract; hyaluronic acid depolymerization inhibitors such as Kuritake (Naematoloma sublateritium) extract, Kurokawa (Boletopsis Leucomelas) extract, Mokkin (Hibiscus syriacus) extract, gambir extract, and clove extract; differentiation promoters of keratinocytes such as diisopropylaminodichloroacetic acid, niacin, mevalonic acid, hot spring water, sodium metasilicate, and orange homogenized fruit; and skin barrier enhancers such as β -hydroxy- γ -aminobutyric acid and mevalonic acid; as far as the object of the present invention can be achieved.

Examples

[0023] The present invention will be described in detail by the following Test Examples and Formulation Examples which do not limit the present invention.

Test Example 1 (Hyaluronic acid production test to human normal keratinocytes)

[0024] Human keratinocytes (manufactured by Kurabo Industries, Ltd.) were seeded in a 24-well plate, cultured to confluence in a growth medium, and then 5 mmol/L of N-acetylglucosamine, 0.0001% of retinyl palmitate, 0.0001% of retinyl palmitate + 5 mmol/L of N-acetylglucosamine, 1.0 imol/L of retinoic acid, or 1.0 imol/L of retinoic acid + 5 mmol/L of N-acetylglucosamine were added, respectively. 24 hours after the addition, hyaluronic acid released into the medium was determined. The determination of hyaluronic acid was conducted using a commercially available hyaluronic acid determination kit (manufactured by Chugai Diagnostics Science).

[0025] The effects of test substances were defined as percentage (%) of the amount of hyaluronic acid in a cultured medium without a test substance. The results are shown below.

45	Test substances	Hyaluronic acid production promotion ratio (% \pm S.D.)
	*5 mmol/L of N-acetylglucosamine	155 \pm 11.8
	*0.0001% of retinyl palmitate	123 \pm 16.4
50	*0.0001% of retinyl palmitate + 5 mmol/L of N-acetylglucosamine	264 \pm 65.6
	*1.0 imol/L of retinoic acid	250 \pm 20.8
	*1.0 imol/L of retinoic acid + 5 mmol/L of N-acetylglucosamine	632 \pm 89.7

[0026] By adding 5 mmol/L of N-acetylglucosamine to cultured keratinocytes, the production of hyaluronic acid was increased by 1.55 times as compared with the no-addition group. Consequently, it has been found that N-acetylglu-

5 cosamine promotes the hyaluronic acid production in keratinocytes. By adding 0.0001% of retinyl palmitate alone, or retinoic acid whose effect of promoting the production of hyaluronic acid has already been known alone, the production of hyaluronic acid was increased by 1.23 times or 2.5 times as compared with the no-addition group. By simultaneously adding 0.0001% of retinyl palmitate and 5 mmol/L of N-acetylglucosamine to the culture, the production of hyaluronic acid was remarkably increased by 2.64 times as compared with the no-addition group, and thus the production of hyaluronic acid was increased to the level higher than that achieved by the effect of 1.0 imol/L of retinoic acid. By simultaneously adding 1.0 imol/L of retinoic acid and 5 mmol/L of N-acetylglucosamine, the production of hyaluronic acid was increased by 6.32 times as compared with the no-addition group. Consequently, a noticeable synergic effect of the both substances was recognized.

10

Test Example 2 (Hyaluronic acid production test to human keratinocytes)

15 [0027] In the same manner as in Test Example 1, the test was conducted (n=3). As the test substance, 1 imol/L of retinoic acid (hereinafter referred to as RA), 1 imol/L of retinol (hereinafter referred to as ROH), 0.001% of retinyl palmitate (hereinafter referred to as RPal) and 0.001% of retinyl acetate (hereinafter referred to as RAcc) were used, and the determination was conducted with respect to the case where 5 mmol/L of N-acetylglucosamine (hereinafter referred to as NAG) and each of the above test substances were simultaneously added. The results are shown below and in Fig. 1.

20

	ig/well	S.D.
cont. (no addition)	0.11	0.0043
NAG	0.12	0.0036
RA	0.37	0.0100
NAG + RA	0.81	0.0252
ROH	0.15	0.0061
NAG + ROH	0.27	0.0574
RPal	0.22	0.0156
NAG + RPal	0.45	0.0332
RAcc	0.18	0.0016
NAG + RAcc	0.40	0.0400

25

30 [0028] Retinoic acid-, retinal-, retinyl palmitate-, and retinyl acetate-addition groups increased the production of hyaluronic acid by 3.4, 1.4, 2.0 and 1.6 times, respectively, as compared with the no-addition group. By simultaneously adding together with N-acetylglucosamine, the production of hyaluronic acid was remarkably increased by 7.4, 2.5, 4.1 and 3.6 times, respectively. The addition of N-acetylglucosamine alone exerted lower effect (e.g. 1.1 times) as compared with the no-addition group. Therefore, it has been found that the production of hyaluronic acid is synergically promoted by using these retinoids in combination with N-acetylglucosamine.

40

Test Example 3 (Hyaluronic acid production promotion test to human keratinocytes)

45 [0029] In the same manner as in Test Example 1, the test was conducted and the amount of hyaluronic acid was determined (n=3). As the test substance, 10 imol/L of β -carotene (hereinafter referred to as β CAR), NAG, and NAG + β CAR were used. The results are shown below and in Fig. 2.

50

	ig/well	S.D.
cont. (no addition)	0.14	0.007
β CAR	0.16	0.010
NAG	0.18	0.020
NAG + β CAR	0.35	0.025

55

[0030] N-acetylglucosamine and β -carotene increased the production of hyaluronic acid by 1.3 and 1.1 times as compared with the no-addition group. In case of simultaneously adding both substance, a remarkably high effect of promoting the production of hyaluronic acid (2.5 times) was exerted. Consequently, it has been found that the production of hyaluronic acid in epidermal cells is synergically promoted by using pro-vitamin A such as β -carotene in combination with N-acetylglucosamine.

[0031] Formulation Examples of the dermal hyaluronic acid production promoter of the present invention in various preparation forms will be described.

5 Formulation Examples 1 to 3 (Skin creams)

[0032] According to the following formulation, N-acetylglucosamine and retinyl palmitate were formulated to prepare skin creams. All amounts are expressed by %.

10 (1) Formulation

[0033]

		Formulation Example 1	Formulation Example 2	Formulation Example 3
(A)				
15	Stearic acid	1	1	-
	Isostearic acid	-	-	1
20	Glycerin monostearate	2	2	2
	Behenyl alcohol	2	2	2
25	White beeswax	1	1	-
	Cetyl myristate	1	1	1
	Sorbitan sesquioleate	1	1	1
	N-stearoylphytosphingosine	0.1	0.1	0.1
30	Hydrogenated lecithin	0.1	0.1	0.1
	Vegetable squalane	5	5	5
	Octyldodecyl myristate	5	5	5
	Retinyl palmitate	0.05	0.1	0.1
(B)				
35	N-acetylglucosamine	0.01	0.1	1.0
	1,3-butylene glycol	5	10	5
	Concentrated glycerin	5	5	5
40	Methyl paraoxybenzoate	0.2	0.2	0.2
	Sodium ascorbyl phosphate ester	0.2	0.2	0.2
	γ-aminobutyric acid	0.1	0.1	0.1
	Sodium n-stearoylglutamate	0.2	0.2	0.2
45	Alkyl-modified carboxyvinyl polymer	0.05	0.05	0.005
	Nicotinamide	0.1	0.1	0.1
	Sarcosine	0.1	0.1	0.1
	Purified water	balance	balance	balance

(2) Method of preparation

[0034] The ingredients (A) and (B) were dissolved while heating to 80°C, mixed, cooled while stirring and then cooled to 30°C to prepare skin creams.

50 Formulation Examples 4 to 6 (Lotions)

[0035] According to the following formulation, N-acetylglucosamine and retinyl palmitate were formulated to prepare lotions.

(1) Formulation

[0036]

		Formulation Example 4	Formulation Example 5	Formulation Example 6
5	N-acetylglucosamine	0.1	0.3	1.0
	Retinyl palmitate	0.05	0.05	0.1
	1,3-butylene glycol	5	-	5
10	Dipropylene glycol	-	5	5
	Raffinose	1	1	1
	Ethanol	-	-	1
	Phenoxyethanol	0.2	0.2	0.2
15	Pectin	-	-	0.05
	Xanthan gum	-	-	0.1
	Sodium citrate	0.05	0.05	0.05
	Field, horsetail extract (extracted with ethanol)	0.1	0.1	0.1
20	Diisopropylaminodichloroacetic acid	0.2	0.2	0.2
	γ -amino- β -hydroxybutyric acid	0.2	0.2	0.2
	Sodium hyaluronate	0.001	0.001	0.001
	Dipotassium glycyrrhizinate	0.2	0.2	0.2
25	Kuritake (Naematoloma sublateritium) extract(extracted with ethanol)	0.05	0.05	0.05
	Decaboxycarnosine hydrochloride	0.05	0.05	0.05
	Perfume	0.02	0.02	0.02
30	Purified water	balance	balance	balance

(2) Method of preparation

[0037] The respective ingredients were dissolved while mixing and then stirred to prepare lotions.

Formulation Examples 7 to 9 (Gels)

[0038] According to the following formulation, N-acetylglucosamine and retinyl palmitate were formulated to prepare gels.

(1) Formulation

[0039]

		Formulation Example 7	Formulation Example 8	Formulation Example 9
45	(A)			
	Decamethylcyclopentasiloxane	10	10	10
50	Isostearyl isostearate	1	-	-
	Olive oil	-	1	-
	Macadamia nuts oil	-	-	1
	Eucalyptus oil	0.1	-	0.1
	Hexyldecanol	1	0.1	-
55	POE hydrogenated castor oil (60E.O.)	2	2	2
	Spherical silicon powder	1	1	5

(continued)

		Formulation Example 7	Formulation Example 8	Formulation Example 9	
5	(A)				
	(Note 1) Retinyl palmitate	0.05	0.05	0.05	
	(B)				
10	N-acetylglucosamine	0.1	0.1	0.1	
	Glucosamine	-	0.1	-	
	Glucuronic acid	-	-	0.1	
	1,3-butylen glycol	5	10	5	
	Sorbitol liquid	3	3	3	
15	Polyethylene glycol 4000	1	1	1	
	Carboxyvinyl polymer	0.2	0.2	0.2	
	Sugar ceramide (Note 2)	0.1	0.1	0.1	
	Methyl paraoxybenzoate	0.2	0.2	0.2	
20	Mevalonolactone	0.5	0.5	0.5	
	Disodium edetate	0.02	0.02	0.02	
	Potassium hydroxide	0.05	0.05	0.05	
	Purified water	balance	balance	balance	
25	Note 1: Tospearl 145A manufactured by GE TOSHIBA SILICONE CO.,LTD.				
	Note 2: Bioceramide manufactured by Kibun Food Chemifa Co., Ltd.				

(2) Method of preparation

30 [0040] The ingredients (A) and (B) were dissolved while heating to 60°C, mixed, cooled while stirring and then cooled to 30°C to prepare gels.

Formulation Example 10 to 12 (Lipophilic creams)

35 [0041] According to the following formulation, N-acetylglucosamine and retinyl palmitate were formulated to prepare lipophilic creams.

(1) Formulation

[0042]

		Formulation Example 10	Formulation Example 11	Formulation Example 12	
40	(A)				
45	Co-modified silicon (Note 3)	2	2	2	
	POE-modified silicon dispersion (Note 4)	-	2	-	
	Squalane	-	-	10	
50	Decamethylcyclopentasiloxane	15	20	10	
	Methylpolysiloxane	5	2	3	
	Long-chain branched fatty acid cholesteryl (Note 5)	-	-	3	
	Silicon elastomer dispersion (Note 6)	5	2	-	
55	Retinyl palmitate	0.1	0.1	0.1	

(continued)

		Formulation Example 10	Formulation Example 11	Formulation Example 12
5	(B)			
	N-acetylgluosoamine	0.1	0.1	0.1
	Niacin	0.1	0	-
10	Kuritake (Naematoloma sublateritium) extract (extracted with ethanol)	-	0.1	-
	Orange homogenized fruit extract (Note 7)	-	-	0.1
15	Sodium chloride	1	1	1
	Dipropylene glycol	5	5	5
	Concentrated glycerin	5	5	5
	Raffinose	1	1	1
20	Methyl paraoxybenzoate	0.3	0.3	0.3
	Glycyrrhiza extract (extracted with ethanol)	0.1	0.1	0.1
	N-methyl-L-serine	0.5	0.5	0.5
	Purified water	balance	balance	balance
25	Note 3: ABIL EM90 manufactured by Gold Schmidt Co.			
	Note 4: Silicon BY22-008 manufactured by Dow Corning Toray Silicone Co., Ltd.			
	Note 5: YOFCO CLE-NH manufactured by Nippon Fine Chemical Co., Ltd.			
	Note 6: Torayfil manufactured by Dow Corning Toray Silicone Co., Ltd.			
	Note 7: concentrated fruit juice manufactured by Koei Kogyo Co., Ltd.			

30

(2) Method of preparation

[0043] The ingredients (A) and (B) were dissolved with while heating to 60°C, mixed, cooled while stirring and then cooled to 30°C to prepare lipophilic creams.

35

Formulation Examples 13 to 14 (Lotions)

[0044] According to the following formulation, lotions were prepared.

40

(1) Formulation

[0045]

45

		Formulation Example 13	Formulation Example 14
	N-acetylglucosamine	0.1	0.1
	Retinyl palmitate	0.1	0.2
	POE hydrogenated castor oil (100E.O.)	1.0	1.0
50	Ethanol	8.0	8.0
	3-methyl-4-isopropylphenol	0.1	0.1
	Polyethylene glycol	1.0	1.0
	Dried orange peel extract	0.1	0.1
	Lily extract	0.1	0.1
55	Orchid extract	0.1	0.1
	Dipropylene glycol	3.0	3.0
	Hydroxypropyl cellulose	0.05	0.05

(continued)

		Formulation Example 13	Formulation Example 14
5	Glycyrrhiza leave extract	0.3	0.3
	d1-Camphor	0.01	-
	Menthol	0.02	-
	1-Menthyl glyceryl ether	-	0.1
	Purified water	balance	balance

10

(2) Method of preparation

[0046] The respective ingredients were dissolved while mixing and then stirred to prepare lotions.

15

Formulation Example 15 (Gel)

[0047] According to the following formulation, a gel was prepared.

20

(1) Formulation

[0048]

		Formulation Example 15
(A)		
25	Retinyl palmitate	0.1
	Decaglyceryl stearate	1.0
	Diocetyl ether	0.1
30	Diocetyl carbonate	0.1
	Dipropylene glycol	3.0
	Octyl palmitate	0.1
	Decaglyceryl isostearate	0.5
	Eucalyptus oil	0.01
(B)		
35	N-acetylglucosamine	0.1
	Carboxyvinyl polymer	0.3
	Potassium hydroxide	0.15
40	Wisteria tea extract (Ampelopsis grossedentata extract)	0.2
	Marshmallow extract	0.2
	Edelweiss extract	0.5
45	L-serine	0.01
	Raspberryketone glucoside	0.01
	Disodium edetate	0.02
	Purified water	balance

50

(2) Method of preparation

[0049] The ingredients (A) and (B) were dissolved with heating to 64°C, mixed, cooled while stirring and then cooled to 30°C to prepare gels.

55

Formulation Examples 16 and 17 (O/W emulsions)

[0050] According to the following formulation, O/W emulsions were prepared.

(1) Formulation

[0051]

5		Formulation Example 16	Formulation Example 17
(A)			
10	Retinyl palmitate	0.1	0.1
	Palmitic acid	1.0	1.0
	Ceramide 2	0.01	0.01
	Carnauba wax	1.0	1.0
	Cetyl palmitate	1.0	1.0
15	Macadamia nuts oil	2.0	2.0
	Macadamia nuts oil fatty acid phytosteryl(Dihydrocholesteryl Macadamiate)	0.5	0.5
	γ -orizanol	0.05	0.05
	Phytosterol (GLYCINE SOJA (SOYBEAN) STEROL)	0.1	0.1
20	Jojoba oil	1.0	1.0
	Jojoba alcohol	0.1	0.1
	Monoglyceryl hydroxystearate (Salacos MG, manufactured by Nishin Oil Co., Ltd.)	0.3	0.3
25	(B)		
	N-acetylglucosamine	0.1	0.1
	Montmorillonite	0.2	0.2
30	Xanthan gum	0.05	0.05
	Potassium N-stearoyl glutamate	0.3	0.3
	Starch	0.001	0.001
	Olive leaf extract	0.1	0.1
	Maltitol liquid	0.1	0.1
35	Touchuukasou extract (Cordyceps Sinensis Extract)	0.1	0.1
	Hoelen extract	0.1	0.1
	Kakyoku extract (Pyracantha Fortuneana Fruit Extract)	0.1	0.1
40	Ascorbic acid 2-glucoside (Ascorbyl Glucoside)	-	1.0
	Potassium hydroxide	-	0.2
	Purified water	balance	balance

(2) Method of preparation

45 [0052] After the ingredient (B) was mixed and heated to 80°C, an oil phase obtained by melting the ingredient (A) while heating to 80°C was added. Then, the mixture was emulsified while stirring using a homomixer to prepare O/W emulsions.

50 INDUSTRIAL APPLICABILITY

55 [0053] As described above, the synergistic effect of promoting the hyaluronic acid production is exerted by using N-acetylglucosamine, a retinoid and/or pro-vitamin A in combination. By applying the external skin care composition of the present invention, the hyaluronic acid production, as a cell matrix ingredient, is promoted, thus making it possible to prevent aging of human skin (retention of firmness, elasticity and moisture of the skin). Therefore, the external skin care composition of the present invention is useful for use in medicaments, quasi-drugs, cosmetic compositions, bath medicines, hair growth promoters and scalp tonics.

Claims

1. An external skin care composition comprising N-acetylglucosamine and at least one member selected from the group consisting of a retinoid and pro-vitamin A.
5
2. The external skin care composition according to claim 1, wherein said retinoid is at least one member selected from the group consisting of all-trans-retinol, 13-cis-retinol, all-trans-retinoic acid, 13-cis-retinoic acid, retinyl palmitate, retinyl acetate and retinyl propionate.
- 10 3. The external skin care composition according to claim 1, wherein said pro-vitamin A is selected from the group consisting of α -carotene, β -carotene, γ -carotene, cryptoxanthin and echinenone.
- 15 4. The external skin care composition according to any one of claims 1 to 3, which contains N-acetylglucosamine in the amount of 0.001 to 10% by weight based on the total amount of said composition and a retinoid and/or pro-vitamin A in the amount of 0.0001 to 10% by weight based on the total amount of said composition
5. The external skin care composition according to any one of claims 1 to 4, which is a cosmetic composition.
- 20 6. A makeup method for preventing or improving wrinkled skin, dry skin, tanned skin or aged skin, which comprises applying the external skin care composition according to any one of claims 1 to 5 onto the skin.

25

30

35

40

45

50

55

Fig.1





Fig. 2



INTERNATIONAL SEARCH REPORT		International application No. PCT/JP02/02271
A. CLASSIFICATION OF SUBJECT MATTER Int.Cl ⁷ A61K31/7008, 31/07, 31/203, 7/00, 7/40, 7/42, A61P17/16		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Int.Cl ⁷ A61K31/7008, 31/07, 31/203, 7/00, 7/40, 7/42, A61P17/16		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Jitsuyo Shinan Koho 1926-1992 Toroku Jitsuyo Shinan Koho 1994-1996 Kokai Jitsuyo Shinan Koho 1971-1992 Jitsuyo Shinan Toroku Koho 1996-2002		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CA (STN)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, A	JP 2002-68957 A (Kanebo, Ltd.), 08 March, 2002 (08.03.02), Examples 6 to 8 (Family: none)	1-5
A	JP 2001-2551 A (Kanebo, Ltd.), 09 January, 2001 (09.01.01), Full text (Family: none)	1-5
A	JP 2000-136147 A (Lion Corp.), 16 May, 2000 (16.05.00), Par. No. [0006] (Family: none)	1-5
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search 02 May, 2002 (02.05.02)		Date of mailing of the international search report 21 May, 2002 (21.05.02)
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer Telephone No.
Facsimile No.		

Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP02/02271

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 6

because they relate to subject matter not required to be searched by this Authority, namely:

Claim 6 pertains to methods for treatment of the human body by surgery or therapy and thus relates to a subject matter which this International Searching Authority is not required, under the provisions of Article 17(2)(a)(i) of the PCT and Rule 39.1(iv) of the Regulations under the PCT, to search.

2. Claims Nos.:

because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.